TRCT
OCUL icon

Tower Research Capital (TRC)’s Ocular Therapeutix OCUL Stock Holding History

Tower Research Capital (TRC)’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Sell
13,449
-10,417
-44% -$99.3K ﹤0.01% 2083
2025
Q4 		$290K Buy
23,866
+18,204
+322% +$221K 0.01% 1169
2025
Q3 		$66.2K Sell
5,662
-30,635
-84% -$366K ﹤0.01% 2304
2025
Q2 		$337K Buy
36,297
+32,608
+884% +$255K 0.01% 1321
2025
Q1 		$27K Sell
3,689
-5,170
-58% -$39.7K ﹤0.01% 2692
2024
Q4 		$75.7K Buy
8,859
+8,446
+2,045% +$82.4K ﹤0.01% 2318
2024
Q3 		$3.59K Sell
413
-14,983
-97% -$123K ﹤0.01% 4813
2024
Q2 		$105K Buy
15,396
+13,714
+815% +$84.7K ﹤0.01% 2548
2024
Q1 		$15.3K Sell
1,682
-8,074
-83% -$57.3K ﹤0.01% 3251
2023
Q4 		$43.5K Buy
9,756
+5,730
+142% +$16.9K ﹤0.01% 3222
2023
Q3 		$12.6K Buy
4,026
+1,666
+71% +$6.82K ﹤0.01% 3878
2023
Q2 		$12.2K Sell
2,360
-166
-7% -$987 ﹤0.01% 3896
2023
Q1 		$13K Sell
2,526
-14,159
-85% -$67.2K ﹤0.01% 3991
2022
Q4 		$47K Buy
16,685
+9,592
+135% +$31.8K ﹤0.01% 2401
2022
Q3 		$29K Buy
7,093
+1,442
+26% +$7.26K ﹤0.01% 3630
2022
Q2 		$23K Buy
5,651
+4,228
+297% +$16K ﹤0.01% 3658
2022
Q1 		$7K Sell
1,423
-1,429
-50% -$7.92K ﹤0.01% 4744
2021
Q4 		$20K Sell
2,852
-1,621
-36% -$12.6K ﹤0.01% 3676
2021
Q3 		$44K Sell
4,473
-3,809
-46% -$42.8K ﹤0.01% 3062
2021
Q2 		$118K Buy
8,282
+4,031
+95% +$61.3K ﹤0.01% 2296
2021
Q1 		$70K Sell
4,251
-351
-8% -$6.76K ﹤0.01% 2857
2020
Q4 		$95K Sell
4,602
-52,687
-92% -$782K ﹤0.01% 2399
2020
Q3 		$436K Buy
57,289
+47,615
+492% +$395K ﹤0.01% 1834
2020
Q2 		$81K Buy
9,674
+7,582
+362% +$50.3K ﹤0.01% 2644
2020
Q1 		$10K Buy
+2,092
New +$10.3K ﹤0.01% 2030
2019
Q4 		– Sell
-723
Closed -$2K – 4129
2019
Q3 		$2K Sell
723
-1,198
-62% -$5.36K ﹤0.01% 3713
2019
Q2 		$8K Sell
1,921
-12,187
-86% -$45.1K ﹤0.01% 2697
2019
Q1 		$56K Buy
14,108
+4,597
+48% +$18.5K ﹤0.01% 1720
2018
Q4 		$38K Buy
9,511
+8,919
+1,507% +$49.2K ﹤0.01% 1469
2018
Q3 		$4K Sell
592
-2,247
-79% -$14.1K ﹤0.01% 3206
2018
Q2 		$19K Buy
2,839
+2,262
+392% +$15.5K ﹤0.01% 2469
2018
Q1 		$4K Sell
577
-6,143
-91% -$34.6K ﹤0.01% 2798
2017
Q4 		$30K Buy
6,720
+1,445
+27% +$7.38K ﹤0.01% 1737
2017
Q3 		$33K Buy
+5,275
New +$34K ﹤0.01% 2359
2016
Q4 		– Sell
-1,397
Closed -$9K – 4230
2016
Q3 		$9K Sell
1,397
-1,508
-52% -$9.19K ﹤0.01% 2153
2016
Q2 		$14K Buy
+2,905
New +$28.8K ﹤0.01% 2540
2016
Q1 		– Sell
-1,026
Closed -$10K – 4687
2015
Q4 		$10K Buy
+1,026
New +$11.1K ﹤0.01% 2130
2015
Q2 		– Sell
-509
Closed -$21K – 4838
2015
Q1 		$21K Buy
+509
New +$16.7K ﹤0.01% 2204

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tower Research Capital (TRC)'s OCUL Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Ocular Therapeutix (OCUL) stake by 44% in Q1 2026, selling an estimated $99.3K and leaving 13,449 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #2083.

Tower Research Capital (TRC) first reported a position in OCUL in Q1 2015 and has held it in 38 quarters since. The position peaked at $436K in Q3 2020. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Tower Research Capital (TRC) held 13,449 shares of Ocular Therapeutix worth $114K as of Q1 2026.
  • Tower Research Capital (TRC) sold 10,417 Ocular Therapeutix shares in Q1 2026, an estimated $99.3K.
  • Ocular Therapeutix made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2083 holding.
  • Tower Research Capital (TRC) first reported a position in Ocular Therapeutix in Q1 2015 and has held it in 38 quarters since.
  • Tower Research Capital (TRC)'s Ocular Therapeutix position peaked at $436K in Q3 2020.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.